Focus on the ONTARGET results

Henry L. Elliott

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Blockade of the renin-angiotensin system (RAS) has become an integral component of the treatment of patients at increased cardiovascular risk. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) studied 23 400 high-risk cardiovascular patients and compared the effectiveness of telmisartan with that of ramipril and showed that the two drugs were 'therapeutically equivalent'. Telmisartan is now the only angiotensin II blocker with clinical trial evidence of cardiovascular protection equivalent to that of ramipril, which is widely regarded as the 'reference' drug for RAS blockade in patients at increased cardiovascular risk. Despite the prior exclusion of patients intolerant of angiotensin-converting enzyme inhibitors drugs, there were fewer discontinuations in the telmisartan group, and so telmisartan had a superior overall efficacy/tolerability ratio.
LanguageEnglish
PagesS8-S10
JournalJournal of Hypertension
Volume27
Issue numberSupplement 2
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Ramipril
Renin-Angiotensin System
Pharmaceutical Preparations
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
telmisartan
Clinical Trials

Keywords

  • angiotensin-converting enzyme inhibitor
  • angiotensin receptor blocker
  • cardiovascular risk
  • renin-angiotensin system

Cite this

Elliott, Henry L. / Focus on the ONTARGET results. In: Journal of Hypertension. 2009 ; Vol. 27, No. Supplement 2. pp. S8-S10.
@article{5511bc466bb0418f85b2ce49a1966588,
title = "Focus on the ONTARGET results",
abstract = "Blockade of the renin-angiotensin system (RAS) has become an integral component of the treatment of patients at increased cardiovascular risk. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) studied 23 400 high-risk cardiovascular patients and compared the effectiveness of telmisartan with that of ramipril and showed that the two drugs were 'therapeutically equivalent'. Telmisartan is now the only angiotensin II blocker with clinical trial evidence of cardiovascular protection equivalent to that of ramipril, which is widely regarded as the 'reference' drug for RAS blockade in patients at increased cardiovascular risk. Despite the prior exclusion of patients intolerant of angiotensin-converting enzyme inhibitors drugs, there were fewer discontinuations in the telmisartan group, and so telmisartan had a superior overall efficacy/tolerability ratio.",
keywords = "angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, cardiovascular risk, renin-angiotensin system",
author = "Elliott, {Henry L.}",
year = "2009",
month = "6",
doi = "10.1097/01.hjh.0000354512.14086.2a",
language = "English",
volume = "27",
pages = "S8--S10",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "Supplement 2",

}

Focus on the ONTARGET results. / Elliott, Henry L.

In: Journal of Hypertension, Vol. 27, No. Supplement 2, 06.2009, p. S8-S10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Focus on the ONTARGET results

AU - Elliott, Henry L.

PY - 2009/6

Y1 - 2009/6

N2 - Blockade of the renin-angiotensin system (RAS) has become an integral component of the treatment of patients at increased cardiovascular risk. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) studied 23 400 high-risk cardiovascular patients and compared the effectiveness of telmisartan with that of ramipril and showed that the two drugs were 'therapeutically equivalent'. Telmisartan is now the only angiotensin II blocker with clinical trial evidence of cardiovascular protection equivalent to that of ramipril, which is widely regarded as the 'reference' drug for RAS blockade in patients at increased cardiovascular risk. Despite the prior exclusion of patients intolerant of angiotensin-converting enzyme inhibitors drugs, there were fewer discontinuations in the telmisartan group, and so telmisartan had a superior overall efficacy/tolerability ratio.

AB - Blockade of the renin-angiotensin system (RAS) has become an integral component of the treatment of patients at increased cardiovascular risk. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) studied 23 400 high-risk cardiovascular patients and compared the effectiveness of telmisartan with that of ramipril and showed that the two drugs were 'therapeutically equivalent'. Telmisartan is now the only angiotensin II blocker with clinical trial evidence of cardiovascular protection equivalent to that of ramipril, which is widely regarded as the 'reference' drug for RAS blockade in patients at increased cardiovascular risk. Despite the prior exclusion of patients intolerant of angiotensin-converting enzyme inhibitors drugs, there were fewer discontinuations in the telmisartan group, and so telmisartan had a superior overall efficacy/tolerability ratio.

KW - angiotensin-converting enzyme inhibitor

KW - angiotensin receptor blocker

KW - cardiovascular risk

KW - renin-angiotensin system

UR - http://dx.doi.org/10.1097/01.hjh.0000354512.14086.2a

U2 - 10.1097/01.hjh.0000354512.14086.2a

DO - 10.1097/01.hjh.0000354512.14086.2a

M3 - Article

VL - 27

SP - S8-S10

JO - Journal of Hypertension

T2 - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - Supplement 2

ER -